Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC) by Bergmeijer, Thomas O. et al.
20 December 2021
Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-
Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC) / Bergmeijer, Thomas O.;
Reny, Jean-Luc; Pakyz, Ruth E.; Gong, Li; Lewis, Joshua P.; Kim, Eun-Young; Aradi, Daniel; Fernandez-Cadenas,
Israel; Horenstein, Richard B.; Lee, Ming Ta Michael; Whaley, Ryan M.; Montaner, Joan; Gensini, Gian Franco; Cleator,
John H.; Chang, Kiyuk; Holmvang, Lene; Hochholzer,
Original Citation:
Genome-wide and candidate gene approaches of clopidogrel efficacy using





(Article begins on next page)
La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla
Policy per l'accesso aperto dell'Università degli Studi di Firenze (https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf)
Availability:
This version is available at: 2158/1119636 since: 2020-10-23T15:52:45Z
Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:
FLORE




Genome-wide and candidate gene approaches of clopidogrel 
efficacy using pharmacodynamic and clinical endpoints - 
Rationale and design of the International Clopidogrel 
Pharmacogenomics Consortium (ICPC)
Thomas O. Bergmeijer, MD1, Jean-Luc Reny, MD2, Ruth E. Pakyz, MS3, Li Gong, PhD4, 
Joshua P. Lewis, PhD3, Eun-Young Kim, MD5, Daniel Aradi, MD6, Israel Fernandez-
Cadenas, PhD7, Richard B. Horenstein, MD3, Ming Ta Michael Lee, PhD8, Ryan M. Whaley4, 
Joan Montaner, MD9, Gian Franco Gensini, MD10, John H. Cleator, MD11, Kiyuk Chang, 
MD12, Lene Holmvang, MD13, Willibald Hochholzer, MD14, Dan M. Roden, MD15, Stefan 
Winter, PhD16, Russ B. Altman, MD4,36,37, Dimitrios Alexopoulos, MD17, Ho-Sook Kim, 
PhD18, Jean-Pierre Déry, MD19, Meinrad Gawaz, MD20, Kevin Bliden, MBA21, Marco 
Valgimigli, MD22, Rossella Marcucci, MD23, Gianluca Campo, MD24, Elke Schaeffeler, 
PhD16, Nadia P. Dridi, MD13, Ming-Shien Wen, MD34, Jae Gook Shin, MD18, Tabassome 
Simon, MD25, Pierre Fontana, MD26, Betti Giusti, PhD23, Tobias Geisler, MD20, Michiaki 
Kubo, MD27, Dietmar Trenk, PhD28, Jolanta M. Siller-Matula, MD29, Jurriën M. ten Berg, MD, 
PhD1, Paul A. Gurbel, MD21, Jean-Sebastien Hulot, MD30, Braxton D. Mitchell, PhD31,35, 
Matthias Schwab, MD16,32, Marylyn DeRiggi Ritchie, PhD33, Teri E. Klein, PhD4,37, Alan R. 
Shuldiner, MD3, and the ICPC Investigators
1St Antonius Center for Platelet Function Research, Department of Cardiology, St Antonius 
Hospital Nieuwegein, The Netherlands 2Internal Medicine, Béziers Hospital, France; Geneva 
Platelet Group, University of Geneva School of Medicine; Department of Internal Medicine, 
Rehabilitation and Geriatrics, University Hospitals of Geneva, Switzerland 3Department of 
Medicine, Program for Personalized and Genomic Medicine, University of Maryland, Baltimore, 
USA 4Department of Biomedical Data Science, Stanford University, USA 5Department of Clinical 
Pharmacology, Inje University Busan Paik Hospital, South Korea 6Heart Center Balatonfüred and 
Heart and Vascular Center, Semmelweis University Budapest, Hungary 7Stroke 
Pharmacogenomics and Genetics, Fundació Docencia i Recerca Mutuaterrassa; Neurovascular 
Research Laboratory, Vall d’Hebron Institute of Research, Spain 8Genomic Medicine Institute, 
Geisinger Health System, Danville, PA, USA 9Neurovascular Research Laboratory, Vall d’Hebron 
Institute of Research, Spain 10Department of Experimental and Clinical Medicine, University of 
Florence, Italy 11Departments of Medicine and Pharmacology, Vanderbilt University School of 
Medicine, Nashville, USA 12Cardiovascular Center and Cardiology Division, Seoul St. Mary’s 
Hospital, College of Medicine, The Catholic University, of Korea, South Korea 13Department of 
Cardiology and Cardiac Catheterization Laboratory, Rigshospitalet, University of Copenhagen, 
Denmark 14University Heart Center Freiburg, Bad Krozingen, Department of Cardiology and 
Correspondence: Alan R. Shuldiner, MD, University of Maryland School of Medicine, Medical Science Teaching Facility, Room 
379, 10 South Pine Street, Baltimore, Maryland 21201, Telephone: 410-706-1623, ashuldin@medicine.umaryland.edu. 
HHS Public Access
Author manuscript
Am Heart J. Author manuscript; available in PMC 2019 April 01.
Published in final edited form as:













Angiology II, Bad Krozingen, Germany 15Departments of Medicine, Pharmacology, and 
Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, USA 16Dr Margarete 
Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Tübingen, 
Germany 17Department of Cardiology, Patras University Hospital, Patras, Greece 18Department of 
Pharmacology and Pharmacogenomics Research Center, College of Medicine, Inje University, 
South Korea 19Quebec Heart and Lung Institute, Canada 20Department of Cardiology and 
Cardiovascular Medicine, University Hospital Tübingen, Germany 21Inova Center for Thrombosis 
Research and Drug Development. Inova Heart and Vascular Institute, Falls Church, VA, USA 
22Department of Cardiology, Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, 
Switzerland 23Department of Experimental and Clinical Medicine, University of Florence; 
Atherothrombotic Diseases Center, Careggi Hospital, Florence, Italy 24Cardiology Unit, Azienda 
Ospedaliera Universitria di Ferrara, Cona (FE) and Maria Cecilia Hospital, GVM Care and 
Research, Cotignola (RA),, Italy 25APHP, Saint Antoine Hospital, Paris, France 26Geneva Platelet 
Group, University of Geneva School of Medicine; Division of Angiology and Haemostasis, 
University Hospitals of Geneva, Switzerland 27Laboratory for Genotyping Development, RIKEN 
Center for Integrative Medical Sciences, Japan 28Department of Cardiology and Cardiovascular 
Medicine, University Hospital Tübingen, Germany 29Department of Cardiology, Medical University 
of Vienna, Austria 30Sorbonne Universités, UPMC Univ Paris 06, Institute of Cardiometabolism 
and Nutrition (ICAN), Pitié-Salpêtrière Hospital, F-75013 Paris, France 31Department of Medicine, 
University of Maryland, Baltimore, USA 32Department of Clinical Pharmacology, University 
Hospital, Tübingen, Germany 33Department of Biomedical and Translational Informatics, 
Geisinger Health System, Danville, PA, USA 34Division of Cardiology, Department of Internal 
Medicine, Chang Gung Memorial Hospital, Linkou and School of Medicine, Chang Gung 
University, Taiwan 35Geriatric Research, Education and Clinical Center, Veterans Affairs Medical 
Center, Baltimore, MD 36Departments of Bioengineering and Genetics, Stanford University, USA 
37Department of Medicine, Stanford University, USA
Abstract
Rationale—The P2Y12 receptor inhibitor clopidogrel is widely used in patients with acute 
coronary syndrome, percutaneous coronary intervention or ischemic stroke. Platelet inhibition by 
clopidogrel shows wide inter-patient variability and high on-treatment platelet reactivity is a risk 
factor for atherothrombotic events, particularly in high-risk populations. CYP2C19 polymorphism 
plays an important role in this variability, but heritability estimates suggest that additional genetic 
variants remain unidentified. The aim of the International Clopidogrel Pharmacogenomics 
Consortium (ICPC) is to identify genetic determinants of clopidogrel pharmacodynamics and 
clinical response.
Study design—Based on the data published on www.clinicaltrials.gov, clopidogrel intervention 
studies containing genetic and platelet function data were identified for participation. Lead 
investigators were invited to share DNA samples, platelet function test results, patient 
characteristics and cardiovascular outcomes, to perform candidate gene and genome-wide 
association studies.
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Results—In total, 17 study sites from 13 countries participate in the ICPC, contributing 
individual patient data from 8,829 patients. Available adenosine diphosphate (ADP) stimulated 
platelet function tests included Vasodilator-Stimulated Phosphoprotein (VASP) assay, Light 
Transmittance Aggregometry (LTA) and the VerifyNow P2Y12 assay. A proof of principle analysis 
based on genotype data provided by each group showed a strong and consistent association 
between CYP2C19*2 and platelet reactivity (p-value = 5.1×10−40).
Conclusion—The ICPC aims to identify new loci influencing clopidogrel efficacy by using 
state-of-the-art genetic techniques in a large cohort of clopidogrel-treated patients in order to 
better understand the genetic basis of on-treatment response variability.
Keywords
clopidogrel; anti-platelet therapy; genome-wide association; CYP2C19; genotyping; candidate 
genes; pharmacogenetics; platelet reactivity; percutaneous coronary intervention; acute coronary 
syndrome; coronary artery disease
Background
In patients with coronary artery disease in which percutaneous coronary intervention (PCI) 
is performed, dual antiplatelet therapy with the cyclooxygenase-1 (COX-1) inhibitor aspirin 
and a P2Y12 receptor inhibitor, commonly clopidogrel, is the recommended antiplatelet 
treatment to prevent recurrent atherothrombotic events, like stent thrombosis.1, 2 Although 
the incidence of stent thrombosis is declining in recent years due to advances in clinical care, 
such as utilization of new stent designs, it remains a serious complication with a high 
mortality rate.3 In addition, medical management with clopidogrel is effective in the 
prevention of recurrent cardiovascular events in patients with acute coronary syndrome 
(ACS), ischemic stroke and peripheral arterial disease.4–6 However, substantial variability in 
on-clopidogrel platelet reactivity is well-documented. This variability leads to an increased 
risk for adverse thrombotic and bleeding complications in patients with high or low platelet 
reactivity, respectively.7–9 Multiple factors influence variation in on-clopidogrel platelet 
reactivity, including genetic, anthropometric and clinical variables, as well as drug-drug 
interactions (e.g. calcium channel blockers, certain proton pump inhibitors such as 
omeprazole and esomeprazole, ketoconazole, morphine or St. John’s Wort).10–12 Smoking 
has been correlated to higher platelet inhibition by clopidogrel, but the data are 
controversial.13, 14
Conversion of clopidogrel into its active thiol metabolite by hepatic CYP P450 enzymes 
results in irreversible inhibition of platelet P2Y12 receptors.15 Polymorphisms in enzymes 
which are involved in the two conversion steps, in particular the CYP2C19*2 (rs4244285) 
and CYP2C19*3 (rs4986893) loss-of-function (LoF) alleles, result in lower clopidogrel 
active metabolite levels16, 17, higher levels of on-treatment platelet reactivity7, 17–23, and 
increased risk for on-treatment atherothrombotic events, in particular in the patients with the 
highest thrombotic risk.24–29 The allele frequency of the CYP2C19*2 polymorphism is 
~15% in Caucasian populations and ~29–35% in Asian populations.30, 31 These findings led 
the FDA in 2010 to add a boxed warning to the clopidogrel label, warning physicians that an 
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alternative antiplatelet drug should be considered in CYP2C19*2 homozygote (poor 
metabolizer) patients.32
In addition to the CYP2C19*2 and *3 polymorphisms, there are other genes in which 
polymorphism has been associated with impaired clopidogrel efficacy, such as ABCB1, 
CYP2B6 and PON1. However, their role as determinants of clopidogrel response is 
controversial as the findings could not be reproduced in more recent studies.33–37
In contrast to factors related to increased atherothrombotic risk, the putative gain-of-function 
allele CYP2C19*17 has been correlated with a higher clopidogrel active metabolite level 
and a reduction in on-treatment platelet reactivity.38, 39 However, most of these reports have 
not taken into account that this allele is genetically linked to the CYP2C19*2 allele, i.e., the 
allele containing the *17 polymorphism lacks the *2 polymorphism.40 Also a rare decrease 
of function variant in carboxyesterase 1 (CES1), the enzyme responsible for converting 
clopidogrel into biologically inactive metabolites, has been reported to be associated with 
increased clopidogrel responsivity.40 Recently, exome sequencing of patients with extreme 
pharmacodynamic responses to clopidogrel identified B4GALT2 as a determinant of low on-
treatment platelet reactivity.41 Whether these variants result in better clopidogrel efficacy 
and/or increased bleeding risk remains to be determined.
Despite the relationship between CYP2C19*2 and impaired platelet inhibition, as assessed 
by ex vivo adenosine diphosphate (ADP)-stimulated platelet aggregation, it only accounts 
for approximately 4–12% of the observed inter-individual variation in antiplatelet effect.
34, 42–44 Estimates suggest the heritability of the variability in response to clopidogrel to be 
as high as 70%, suggesting other genetic factors influencing clopidogrel efficacy.44
A previously conducted genome wide association study (GWAS) of clopidogrel response in 
429 Amish subjects supported CYP2C19*2 as the single major genetic determinant of 
clopidogrel response.44 However, there were several additional common variants in or near 
other genes that showed nominal evidence of association with clopidogrel response in that 
investigation, but did not achieve genome-wide significance (p-value ~ 10−6). If some of 
these variants represent true positive signals, they may be uncovered by larger sample sizes. 
To this end, the International Clopidogrel Pharmacogenomics Consortium (ICPC) was 
established to better define the genetic architecture of variable clopidogrel response. 
Participating study sites (N=17) contributed DNA samples, results of ADP-induced platelet 
function testing and clinical outcome data of patients treated with clopidogrel. A high 
quality genomic discovery resource was assembled consisting of DNA samples, 
pharmacodynamic data, major adverse cardiovascular outcomes, and relevant clinical 
characteristics.
This article describes the characteristics of the ICPC and provides a framework for the 
organization and execution of large pharmacogenetics studies.
Bergmeijer et al. Page 4














Study design and population
An organizing committee of international pharmacogenomics investigators was established 
to define the scientific goals of the ICPC. These goals were to identify genetic variants that 
influence platelet aggregation and secondary clinical events in clopidogrel-treated subjects 
with the long-term objective of supporting the use of genetic information that would allow 
clinicians to make more informed treatment decisions for their patients requiring antiplatelet 
therapy.
The organizing committee invited 150 lead investigators of clopidogrel-related clinical 
studies registered in www.clinicaltrials.gov as of June 2011 to participate. Criteria for 
participation included availability of on-clopidogrel platelet reactivity data, availability of 
DNA samples for genetic analysis, and for secondary analysis, availability of clinical 
outcomes; however, studies did not have to fulfill all of these criteria. Eligible studies had to 
have a minimum of 50 planned enrollees. The phenotypic variables must have been obtained 
using predefined protocols and methods, and all patients had to be consented for genetic 
analysis and data sharing. All participating investigators signed a memorandum of 
understanding (included in the Supplemental Data section). Investigators at Stanford 
University (PharmGKB) serve as the centralized data coordinating center. Platelet function 
test results, demographic and cardiovascular outcome data, and other clinical data with a 
potential influence on platelet reactivity, such as age, sex, diabetes, body mass index, renal 
function and medication usage (i.e. calcium channel blockers and proton-pump inhibitors) 
were obtained from each study’s investigators and curated. To date, 17 sites from 13 
countries have joined the ICPC (Table I), contributing data representing 8,829 clopidogrel-
exposed patients. The available sample size, including those with genotyping, and clinical 
outcome data, is described in Table II and Figure 1. DNA was available in 5119 ICPC 
subjects and sent to the University of Maryland where genetic analyses are coordinated. 
Cohort descriptions and the number of patients in which each platelet function test was 
performed are available in the online Supplemental Data section. The ICPC is supported by 
the National Heart, Lung, And Blood Institute of the National Institutes of Health under 
Award Number U01HL105198. The authors are solely responsible for the design and 
conduct of this study, all study analyses, the drafting and editing of the paper and its final 
contents.
Study endpoints
The primary ICPC study endpoint is platelet function. Both platelet function measurements 
in patients on clopidogrel maintenance dose or after adequate loading dose were used, which 
was defined as at least 2 hours between a 600mg clopidogrel loading dose and platelet 
function testing, 6 hours after 300mg clopidogrel loading dose and 5 days after start of 75mg 
maintenance dose without extra loading dose. As platelet function in each study was 
measured using different platelet function tests, i.e. Light Transmittance Aggregometry 
(LTA), Multiplate Analyzer (Multiple Electrode Aggregometry; MEA), Vasodilator-
Stimulated Phosphoprotein (VASP), and VerifyNow P2Y12 assay, measurements were 
standardized across these different tests using a priority system laid out by the Phenotype 
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Subcommittee of the ICPC: VASP assay > VerifyNow P2Y12 > ADP-induced LTA (higher 
ADP concentration > lower ADP concentration) > other tests. The platelet function test was 
then chosen from each site based on the highest ranking assay measured at that site that 
maximized the sample size. To standardize values across the different platelet function 
assays (all of which provide an assessment of ADP-stimulated platelet reactivity albeit 
expressed in different units), we standardized each measurement by subtracting out the mean 
platelet reactivity value and dividing by the standard deviation, thus expressing each 
measurement as a Z-score (i.e., the number of standard deviation units from the mean). 
These transformations were made within each site, thus allowing us to combine results by 
meta analysis despite the use of different platelet function assays. Standardized platelet 
function tests were available in 6270 ICPC subjects.
Secondary ICPC study endpoint included a composite clinical endpoint defined any of 
cardiovascular death, ischemic stroke, or spontaneous myocardial infarction. Stent 
thrombosis, defined by the Academic Research Consortium (ARC) criteria, was also 
ascertained but not considered as part of the composite clinical endpoint.45 This rare but 
potentially lethal complication of stent placement will be analyzed separately. Major 
bleeding complications are captured in the database, although various definitions for 
bleeding were used in different study cohorts. The secondary endpoints were adjudicated 
locally using site-specific criteria. The ICPC includes a total of 5,819 subjects in which all 
components of the combined clinical endpoint are available. In those patients, 290 major 
adverse cardiac events (MACE) were observed (event rate 5.0%) during a mean (standard 
deviation [SD]) follow-up duration of 13 ± 9 months. The event rate is lower compared to 
the clopidogrel treated cohorts in the PLATO and TRITON studies, which might be 
explained by the higher percentage of ACS patients in those cohorts.46, 47 In the subset of 
ICPC with DNA samples, 3426 patients have clinical data of whom 199 major adverse 
cardiac events were observed (event rate 5.8%) during a mean follow-up duration of 14 ± 11 
months.
In addition to the main objectives of the ICPC, ICPC investigators as well as external 
investigators have the opportunity to access the combined data set for ancillary projects. 
Project proposals detailing research aims and analysis plans are reviewed and approved by 
the ICPC Steering Committee. Consortium members will not have access to personal 
identifiers. Consortium phenotype and genotype data will be deposited to public database 
(e.g. dbGAP) in accordance with NIH data sharing policies.
Genotyping
Genotyping will include both a candidate gene approach, in which a small number of genes 
and gene variants will be chosen based upon prior evidence for association with clopidogrel 
response, and an agnostic genome-wide approach using the Illumina Omni Express with 
Exome (OEE) chip, to identify novel loci associated with clopidogrel response. Data will be 
cleaned using the eMERGE QC pipeline.48 eMERGE is the electronic MEdical Record and 
GEnomics Network, a National Human Genome Research Institute (NHGRI) funded 
consortium which has been combining clinical cohorts with biobanks linked to electronic 
health records. The genotype data cleaning process includes evaluation of sample and 
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marker call rate, gender mismatch, duplicate and HapMap concordance, batch effects, 
Hardy-Weinberg equilibrium, sample relatedness and population stratification. For GWAS, 
imputation to the 1000 Genomes reference dataset will be performed using the eMERGE 
Imputation Pipeline which includes SHAPEIT2 for phasing and IMPUTE2 for imputation.49 
eMERGE has developed a robust imputation and quality control pipeline for the combining 
of multiple datasets, which will be appropriate for the ICPC.
Database validation
To validate the ICPC central database, the association between cross-study harmonized 
platelet reactivity and CYP2C19*2 was tested, as this association has been well-described in 
the literature.7, 17–22, 50 All Caucasian patients with site-reported CYP2C19*2 and 
harmonized ADP-induced platelet reactivity phenotype (n=5328) were selected. The 
analysis was adjusted for age and sex. All analyses were performed in SAS version 9.2 (SAS 
Institute Inc., Cary, North Carolina). Results confirmed that CYP2C19*2 was independently 
associated with higher on-treatment platelet reactivity (Beta = 0.37; p-value = 5.1×10−40).
Future directions
The ICPC is a collaborative platform for novel gene discovery related to clopidogrel 
effectiveness. It will serve as a well-powered resource to test new hypotheses and welcomes 
proposals from qualified investigators. ICPC will also serve as a replication cohort for 
genetic variants identified by other research groups worldwide. Proposals for new research 
questions can be send by email to the corresponding author of this paper.
Concluding remarks
With the introduction of the newer P2Y12 receptor inhibitors prasugrel and ticagrelor, 
multiple antiplatelet drugs are now available for clinicians to use. Although prasugrel and 
ticagrelor are more effective in reducing atherothrombotic events in ACS patients, they 
increase the risk of bleeding compared to clopidogrel, and are more expensive.46, 47 Given 
that alternative treatment options exist and pharmacodynamic and genetic testing options are 
available to predict or test the efficacy of clopidogrel, development of personalized 
antiplatelet strategies, to reduce atherothrombotic events and risk of bleeding, might 
significantly enhance patient care and potentially reduce costs; thus additional studies are 
warranted. Nevertheless, finding the optimal treatment strategy has proven to be difficult so 
far, as recent studies using different treatment modification strategies show contrasted 
results, owing in part to the different clinical settings and population vascular risk levels in 
the various studies.51–57 Identification of novel gene variants that predict clopidogrel 
efficacy may provide important information to improve predictive algorithms for genotype-
directed therapy. These studies also promise to provide new insights into platelet biology 
and to identify novel targets for more effective and safe antiplatelet therapy.
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The aim of the ICPC is to find novel genetic markers which influence clopidogrel efficacy, 
using GWAS and candidate gene approaches combined with pharmacodynamic and clinical 
outcome data.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure describing the subset of patients in which platelet function data, clinical outcome data 
and/or a DNA sample is available for analysis. Total number of patients is 8829.
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Table I
Participating Study Sites
ICPC Primary Investigator Country No. patients
J.G. Shin South Korea 2280
J.M. ten Berg Netherlands 1024
D. Trenk Germany 797
G.F. Gensini Italy 736
J. Cleator, D. Roden USA 693
A. Shuldiner USA 687
P. Fontana, J. L. Reny Switzerland, France 538
M. Schwab, T. Geisler Germany 442
J.M. Siller-Matula Austria 416
J. Déry Canada 325
M. Valgimigli, G. Campo Italy 234
D. Aradi Hungary 192
M. Lee Taiwan 160
L. Holmvang Denmark 106
P. Gurbel USA 79
I. Fernández-Cadenas Spain 70
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Table II








  White 70.8 94.6
  Asian 27.9 4.9
  Other 1.3 0.5
Gender (male) 71.2 76.4
Age (years) 62.8 ± 13.0 63.5 ± 12.5
Body Mass Index (kg/m2) 26.9 ± 4.7 27.4 ± 4.4
Diabetes 26.0 23.3
Current smoker 19.5 22.3
Hypercholesterolemia 53.8 66.1
LVEF <35% 5.2 6.1
Aspirin use 94.7 93.2
Statin use 75.0 82.3
CYP2C19 *2 carrier (site-reported) 35.7 31.9
CYP2C19 *17 carrier (site-reported) 28.6 36.2
Coronary artery disease (indication for clopidogrel use) 81.4 94.3
  - acute coronary syndrome 33.7 44.2
  - PCI performed 92.5 87.6
    - for acute coronary syndrome 36.4 56.6
    - for non-urgent PCI 63.6 43.4
Data are expressed in % or Mean ± SD
*
All patients with both a DNA sample and platelet function test result available
Abbreviations: LVEF = left ventricular ejection fraction, PCI = percutaneous coronary intervention, SD = standard deviation
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